[Letrozole versus gonadotropin-releasing hormone antagonist during luteal phase in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial].

Cheng ZX, Kong G, Zhang CL, Zhao YN

Zhonghua fu chan ke za zhi1 Jan 2020Cited by 2 (Europe PMC)

PMID32074767DOI10.3760/cma.j.issn.0529-567x.2020.01.003PepBankPUB-32074767

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In infertile women at high OHSS risk, moderate and severe OHSS incidence did not differ significantly between cetrorelix and letrozole.
In plain wordsIn women at high OHSS risk, moderate and severe OHSS rates did not differ significantly between cetrorelix and letrozole.
Peptide
Cetrorelix
Outcome
No significant changeModerate and severe OHSS
Study
n = 99
Comparator
Letrozole 7.5 mg daily for 3 days
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.25 mg daily · subcutaneous · 3 daysAs given in this study (human).
Measurements
OHSS incidence
10.4%
cetrorelix
OHSS events
5 patients
cetrorelix
OHSS incidence
11.8%
letrozole
OHSS events
6 patients
letrozole
Source sentences
Summary
The incidence of moderate and severe OHSS was found no significantly difference between letrozole group [11.8%(6/51)] and GnRH antagonist group [10.4%(5/48);P>0.05].
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 99 infertile women undergoing in vitro fertilization and embryo transfer or intracytoplasmic sperm injection with high risk for OHSS were enrolled in this randomized controlled trial.
Summary · context
Both groups received support therapy combined with embryo cryopreservation.
Report a problemFND-3207476701
02HumanRandomized controlled trialEfficacy outcome
In women at high OHSS risk, estradiol on days 3, 5 and 8 after oocyte retrieval was significantly higher with cetrorelix than with letrozole.
In plain wordsIn women at high OHSS risk, estradiol on days 3, 5 and 8 after retrieval was higher with cetrorelix than with letrozole.
Peptide
Cetrorelix
Outcome
IncreaseEstradiol on days 3, 5 and 8 after retrieval
Study
n = 99
Comparator
Letrozole 7.5 mg daily for 3 days
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · subcutaneous · 3 daysAs given in this study (human).
Measurements
Estradiol
15,210 pmol/L
cetrorelix day 3
Estradiol
1417 pmol/L
letrozole day 3
Estradiol
18,680 pmol/L
cetrorelix day 5
Estradiol
1692 pmol/L
letrozole day 5
Estradiol
3582 pmol/L
cetrorelix day 8
Estradiol
239 pmol/L
letrozole day 8
Source sentences
Summary
The estradiol concentration of the indicated days on days 3,5 and 8 after oocytes retrieval in letrozole group and GnRH antagonist group were (1 417±3 543) versus (15 210±9 921) pmol/L, (1 692±4 330) versus (18 680±11 567) pmol/L, (239±336) versus (3 582±5 427) pmol/L, respectively
3 context sentences(design, population, supporting numbers)
Summary · context
compared with GnRH antagonist group, the estradiol level was significantly lower in the letrozole group (all P<0.01).
Summary · context
A total of 99 infertile women undergoing in vitro fertilization and embryo transfer or intracytoplasmic sperm injection with high risk for OHSS were enrolled in this randomized controlled trial.
Summary · context
Both groups received support therapy combined with embryo cryopreservation.
Report a problemFND-3207476702
03HumanRandomized controlled trialEfficacy outcome
In women at high OHSS risk, estradiol on day 5 after oocyte retrieval was significantly higher with cetrorelix than letrozole.
In plain wordsIn women at high OHSS risk, estradiol on day 5 after retrieval was higher with cetrorelix than letrozole.
Peptide
Cetrorelix
Outcome
IncreaseEstradiol on day 5 after retrieval
Study
n = 99
Comparator
Letrozole 7.5 mg daily for 3 days
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · subcutaneous · 3 daysAs given in this study (human).
Measurements
Estradiol
18,680 pmol/L
cetrorelix day 5
Estradiol
1692 pmol/L
letrozole day 5
Source sentences
Summary
The estradiol concentration of the indicated days on days 3,5 and 8 after oocytes retrieval in letrozole group and GnRH antagonist group were (1 417±3 543) versus (15 210±9 921) pmol/L, (1 692±4 330) versus (18 680±11 567) pmol/L, (239±336) versus (3 582±5 427) pmol/L, respectively
3 context sentences(design, population, supporting numbers)
Summary · context
compared with GnRH antagonist group, the estradiol level was significantly lower in the letrozole group (all P<0.01).
Summary · context
A total of 99 infertile women undergoing in vitro fertilization and embryo transfer or intracytoplasmic sperm injection with high risk for OHSS were enrolled in this randomized controlled trial.
Summary · context
Both groups received support therapy combined with embryo cryopreservation.
Report a problemFND-3207476703
04HumanRandomized controlled trialEfficacy outcome
In women at high OHSS risk, estradiol on day 8 after oocyte retrieval was significantly higher with cetrorelix than letrozole.
In plain wordsIn women at high OHSS risk, estradiol on day 8 after retrieval was higher with cetrorelix than letrozole.
Peptide
Cetrorelix
Outcome
IncreaseEstradiol on day 8 after retrieval
Study
n = 99
Comparator
Letrozole 7.5 mg daily for 3 days
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · subcutaneous · 3 daysAs given in this study (human).
Measurements
Estradiol
3582 pmol/L
cetrorelix day 8
Estradiol
239 pmol/L
letrozole day 8
Source sentences
Summary
The estradiol concentration of the indicated days on days 3,5 and 8 after oocytes retrieval in letrozole group and GnRH antagonist group were (1 417±3 543) versus (15 210±9 921) pmol/L, (1 692±4 330) versus (18 680±11 567) pmol/L, (239±336) versus (3 582±5 427) pmol/L, respectively
3 context sentences(design, population, supporting numbers)
Summary · context
compared with GnRH antagonist group, the estradiol level was significantly lower in the letrozole group (all P<0.01).
Summary · context
A total of 99 infertile women undergoing in vitro fertilization and embryo transfer or intracytoplasmic sperm injection with high risk for OHSS were enrolled in this randomized controlled trial.
Summary · context
Both groups received support therapy combined with embryo cryopreservation.
Report a problemFND-3207476704
05HumanRandomized controlled trialEfficacy outcome
In women at high OHSS risk, LH on day 3 after oocyte retrieval was significantly lower with cetrorelix than letrozole.
In plain wordsIn women at high OHSS risk, LH on day 3 after retrieval was lower with cetrorelix than letrozole.
Peptide
Cetrorelix
Outcome
DecreaseLH on day 3 after retrieval
Study
n = 99
Comparator
Letrozole 7.5 mg daily for 3 days
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · subcutaneous · 3 daysAs given in this study (human).
Measurements
LH
0.28 U/L
cetrorelix day 3
LH
0.46 U/L
letrozole day 3
Source sentences
Summary
The luteinizing hormone level in the letrozole group were (0.46±0.40), (0.56±0.55)and (0.67±0.58) U/L on days 3,5 and 8 after oocytes retrieval, which were significantly higher than those of GnRH antagonist group [(0.28±0.28), (0.30±0.19) and (0.45±0.37) U/L, respectively; all P<0.05].
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 99 infertile women undergoing in vitro fertilization and embryo transfer or intracytoplasmic sperm injection with high risk for OHSS were enrolled in this randomized controlled trial.
Summary · context
Both groups received support therapy combined with embryo cryopreservation.
Report a problemFND-3207476705
06HumanRandomized controlled trialEfficacy outcome
In women at high OHSS risk, LH on day 5 after oocyte retrieval was significantly lower with cetrorelix than letrozole.
In plain wordsIn women at high OHSS risk, LH on day 5 after retrieval was lower with cetrorelix than letrozole.
Peptide
Cetrorelix
Outcome
DecreaseLH on day 5 after retrieval
Study
n = 99
Comparator
Letrozole 7.5 mg daily for 3 days
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · subcutaneous · 3 daysAs given in this study (human).
Measurements
LH
0.3 U/L
cetrorelix day 5
LH
0.56 U/L
letrozole day 5
Source sentences
Summary
The luteinizing hormone level in the letrozole group were (0.46±0.40), (0.56±0.55)and (0.67±0.58) U/L on days 3,5 and 8 after oocytes retrieval, which were significantly higher than those of GnRH antagonist group [(0.28±0.28), (0.30±0.19) and (0.45±0.37) U/L, respectively; all P<0.05].
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 99 infertile women undergoing in vitro fertilization and embryo transfer or intracytoplasmic sperm injection with high risk for OHSS were enrolled in this randomized controlled trial.
Summary · context
Both groups received support therapy combined with embryo cryopreservation.
Report a problemFND-3207476706
07HumanRandomized controlled trialEfficacy outcome
In women at high OHSS risk, LH on day 8 after oocyte retrieval was significantly lower with cetrorelix than letrozole.
In plain wordsIn women at high OHSS risk, LH on day 8 after retrieval was lower with cetrorelix than letrozole.
Peptide
Cetrorelix
Outcome
DecreaseLH on day 8 after retrieval
Study
n = 99
Comparator
Letrozole 7.5 mg daily for 3 days
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · subcutaneous · 3 daysAs given in this study (human).
Measurements
LH
0.45 U/L
cetrorelix day 8
LH
0.67 U/L
letrozole day 8
Source sentences
Summary
The luteinizing hormone level in the letrozole group were (0.46±0.40), (0.56±0.55)and (0.67±0.58) U/L on days 3,5 and 8 after oocytes retrieval, which were significantly higher than those of GnRH antagonist group [(0.28±0.28), (0.30±0.19) and (0.45±0.37) U/L, respectively; all P<0.05].
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 99 infertile women undergoing in vitro fertilization and embryo transfer or intracytoplasmic sperm injection with high risk for OHSS were enrolled in this randomized controlled trial.
Summary · context
Both groups received support therapy combined with embryo cryopreservation.
Report a problemFND-3207476707
08HumanRandomized controlled trialEfficacy outcome
In women at high OHSS risk, progesterone levels did not differ significantly between cetrorelix and letrozole.
In plain wordsIn women at high OHSS risk, progesterone levels did not differ significantly between cetrorelix and letrozole.
Peptide
Cetrorelix
Outcome
No significant changeProgesterone
Study
n = 99
Comparator
Letrozole 7.5 mg daily for 3 days
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · subcutaneous · 3 daysAs given in this study (human).
Source sentences
Summary
There was no obvious differences on progesterone levels between letrozole group and GnRH antagonist group (all P>0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 99 infertile women undergoing in vitro fertilization and embryo transfer or intracytoplasmic sperm injection with high risk for OHSS were enrolled in this randomized controlled trial.
Summary · context
Both groups received support therapy combined with embryo cryopreservation.
Report a problemFND-3207476708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.